Graybug Vision Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
35
- Latest Deal Type
-
M&A
- Financing Rounds
-
8
- Investments
-
2
Graybug Vision General Information
Description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Contact Information
Website
www.graybug.visionCorporate Office
- 203 Shoreline Shores Parkway
- Suite 620
- Redwood City, CA 94065
- United States
Corporate Office
- 203 Shoreline Shores Parkway
- Suite 620
- Redwood City, CA 94065
- United States
Graybug Vision Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Graybug Vision Comparisons
Industry
Financing
Details
Graybug Vision Competitors (14)
One of Graybug Vision’s 14 competitors is Foventa Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| CSL Behring | Corporation | King Of Prussia, PA | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Mati Therapeutics | Venture Capital-Backed | Austin, TX |
Graybug Vision Patents
Graybug Vision Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026096796-A1 | Methods for treating acute pancreatitis | Pending | 30-Oct-2024 | ||
| WO-2026072843-A1 | Crac inhibitors for treatment of asparaginase-induced pancreatitis in pediatric patients | Pending | 25-Sep-2024 | ||
| AU-2023209914-A1 | Methods and compositions for treating inflammation injury in the lungs | Pending | 20-Jan-2022 | ||
| EP-4465988-A1 | Methods and compositions for treating inflammation injury in the lungs | Pending | 20-Jan-2022 | ||
| EP-4465988-A4 | Methods and compositions for treating inflammation injury in the lungs | Pending | 20-Jan-2022 | A61K31/4965 |
Graybug Vision Signals
Graybug Vision Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Graybug Vision Acquisitions (2)
Graybug Vision’s most recent deal was a Reverse Merger with CalciMedica. The deal was made on 21-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CalciMedica | 21-Mar-2023 | Reverse Merger | Drug Discovery | ||
| RainBIO | 30-Mar-2022 | Merger/Acquisition | Biotechnology |
Graybug Vision Exits (1)
Graybug Vision’s most recent exit was on 21-Mar-2023 from CalciMedica. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| CalciMedica | 21-Mar-2023 | Completed |
|
Graybug Vision Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| RainBIO | Raleigh, NC | 2020 |
Graybug Vision FAQs
-
When was Graybug Vision founded?
Graybug Vision was founded in 2011.
-
Where is Graybug Vision headquartered?
Graybug Vision is headquartered in Redwood City, CA.
-
What is the size of Graybug Vision?
Graybug Vision has 35 total employees.
-
What industry is Graybug Vision in?
Graybug Vision’s primary industry is Drug Delivery.
-
Is Graybug Vision a private or public company?
Graybug Vision is a Private company.
-
What is Graybug Vision’s current revenue?
The current revenue for Graybug Vision is .
-
How much funding has Graybug Vision raised over time?
Graybug Vision has raised $249M.
-
Who are Graybug Vision’s investors?
Abell Foundation, AffaMed Therapeutics, Brown Advisory, CBC Group (Singapore), and Crown Venture Fund are 5 of 10 investors who have invested in Graybug Vision.
-
Who are Graybug Vision’s competitors?
Foventa Therapeutics, CSL Behring, EyePoint, Amgen, and Mati Therapeutics are some of the 14 competitors of Graybug Vision.
-
When was Graybug Vision acquired?
Graybug Vision was acquired on 20-Mar-2023.
-
Who acquired Graybug Vision?
Graybug Vision was acquired by CalciMedica.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process